Across nearly 44,000 matched patients over 65, GLP-1 users had a 45% lower death risk, researchers report, though they also saw more osteoporosis and retinopathy.
Recap by typeshit. Full story at Newswise.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Lilly is expected to file with the FDA in early 2027. The piece also covers trial weight loss near 30% and warnings about gray-market vials sold as research only.
A Houston Methodist Research Institute study found older adults with MASLD on GLP-1-based treatment had lower risk of hospitalization and death.
Loading…